

Regulated Information

## Bone Therapeutics strengthens Board with the appointment of Jean Stéphane as Chairman

**Jean Stéphane brings extensive biotech and pharma experience**

**Gosselies, Belgium, 20 February 2018, 6 pm CET – BONE THERAPEUTICS** (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that Jean Stéphane has been appointed Chairman of the Board of Directors with immediate effect, replacing Steve Swinson who has informed the Board of his intention to step down.

Jean Stéphane is a highly-experienced life sciences executive, who has served in senior leadership roles at a large number of biotechnology and pharmaceutical companies, most recently as Chairman of TiGenix. Together with the Board of TiGenix, he oversaw the clinical development and market approval of its most advanced allogeneic cell therapy product for the treatment of complex perianal fistulas in Crohn's disease, resulting in Takeda's announced intention to acquire the company for EUR 520 million.

Jean Stéphane was also previously a Member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chief Executive of GSK Biologicals (now GSK Vaccines). During his 40-year tenure, he grew a company of 50 people into a fully integrated worldwide leader in vaccine development, with 12,000 employees.

Jean Stéphane currently serves on the Board of various life sciences companies including TiGenix, Vaxxilon, OncoDNA, CureVac and Bepharbel. Previous board positions include Besix Group, BNP Paribas Fortis, GBL and IBA. For his contribution to the Belgian economy and global public health, he has received diverse business recognitions and was honoured with various titles by the Belgian and British governments.

**Thomas Lienard, Chief Executive Officer of Bone Therapeutics, commented:** *"We are delighted to welcome Jean Stéphane as our new Chairman of the Board. Jean Stéphane has unparalleled experience in drug development and building innovative life science companies and is highly regarded within the sector. We are pleased to have attracted a Chairman of such calibre, a testament to the potential of our unique bone*

● [Le communiqué de presse en français](#)

**For further information, please contact:**

### Bone Therapeutics SA

Thomas Lienard, Chief Executive Officer  
Jean-Luc Vandebroek, Chief Financial Officer  
Tel: +32 (0)2 529 59 90  
[investorrelations@bonetherapeutics.com](mailto:investorrelations@bonetherapeutics.com)

### For Belgium and International Media Enquiries Consilium Strategic Communications

Amber Fennell, Jessica Hodgson, Hendrik Thys and Lindsey Neville  
Tel: +44 (0) 20 3709 5701  
[bonetherapeutics@consilium-comms.com](mailto:bonetherapeutics@consilium-comms.com)

### For French Media and Investor Enquiries NewCap Investor Relations & Financial Communications

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau  
Tel: + 33 (0)1 44 71 94 94  
[bone@newcap.eu](mailto:bone@newcap.eu)

### For US Media and Investor Enquiries Westwicke Partners

John Woolford  
Tel: + 1 443 213 0506  
[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)

cell therapy platform. Jean Stéphenne will be a valuable addition to an already strong Board, as we advance our allogeneic cell therapy platform through critical clinical studies and towards commercialization. I would also like to express my thanks, on behalf of the Board and leadership team, to Steve Swinson, who has provided valuable strategic counsel during his time with the Company.”

**Jean Stéphenne, Chairman of Bone Therapeutics commented:** “Bone Therapeutics is a highly innovative Company at the forefront of developments in bone cell therapy and I am very excited to be joining the Board. I look forward to working closely with Thomas, the rest of the Board and the whole Bone Therapeutics team as we move towards important value inflection points for the Company’s bone cell therapy products for the benefit of patients.”